Scarica l'app Stockscreener
0.2172
16.32%
0.0321
Precedente Chiudi:
$0.1851
Aprire:
$0.22
Volume 24 ore:
2.03M
Relative Volume:
8.74
Capitalizzazione di mercato:
$N/A
Reddito:
$39.55M
Utile/perdita netta:
$-122.93M
Rapporto P/E:
-0.4911
EPS:
-0.4423
Flusso di cassa netto:
$-97.31M
1 W Prestazione:
+16.32%
1M Prestazione:
-51.83%
6M Prestazione:
-75.91%
1 anno Prestazione:
-82.72%
Intervallo 1D:
$0.2141
$0.23
Intervallo di 1 settimana:
$0.2141
$0.23
Portata 52W:
$0.1172
$0.23
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare SGMO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.2221 | 0 | 39.55M | -122.93M | -97.31M | -0.4423 |
VRTX
Vertex Pharmaceuticals Inc
|
427.66 | 107.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
621.06 | 63.21B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.14 | 49.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.82 | 38.20B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.37 | 32.17B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-12-13 | Aggiornamento | Truist | Hold → Buy |
| 2024-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Gregory D - Moomoo
Sangamo (SGMO) executive shares withheld to cover RSU tax obligations - Stock Titan
Sangamo (SGMO) SVP surrenders 4,036 shares for RSU tax withholding - Stock Titan
Sangamo (SGMO) SVP uses 4,036 shares to cover RSU tax - Stock Titan
Sangamo Therapeutics (SGMO) CEO surrenders RSU shares to cover taxes - Stock Titan
Sangamo presents primate data for prion suppressor ST-506 - BioWorld News
Sangamo Therapeutics (SGMO) reports Q1 loss, misses revenue estimates - MSN
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period - TipRanks
Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha
Finance Watch: Sangamo Once Again Nearing The End Of Its Cash - Citeline News & Insights
Sangamo Therapeutics | SCHEDULE 13G: Others - Moomoo
Sangamo Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (OTCMKTS:SGMO) 2026-05-15 - Seeking Alpha
Q1 2026 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Sangamo Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Sangamo Therapeutics (SGMO) Q1 2026 Earnings: EPS -$0.08 vs $0.0 - GuruFocus
Sangamo Therapeutics (SGMO) Advances BLA Submission Amid OTCQB T - GuruFocus
Sangamo Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial Challenges - GuruFocus
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June - MSN
Sangamo Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Sangamo Therapeutics Q1 2026 reveals financial challenges - Investing.com Nigeria
SGMO: BLA submission for Fabry therapy advances as FDA waives need for a second confirmatory study - TradingView
SGMO: Advanced BLA submission for Fabry therapy, FDA support, and strategic capital efforts underway - TradingView
Transcript : Sangamo Therapeutics, Inc., Q1 2026 Earnings Call, May 14, 2026 - marketscreener.com
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2026 FINANCIAL RESULTS - Moomoo
Full Transcript: Sangamo Therapeutics Q1 2026 Earnings Call - Benzinga
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - Moomoo
Sangamo Therapeutics Inc (NASDAQ:SGMO) Misses Q1 2026 Estimates, Stock Plunges 15.6% - ChartMill
SANGAMO THERAPEUTICS ($SGMO) Releases Q1 2026 Earnings - Quiver Quantitative
More on Sangamo Therapeutics - MSN
Sangamo Therapeutics Q1 2026 earnings preview - MSN
Sangamo: Q1 Earnings Snapshot - Barchart.com
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - The Manila Times
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Sangamo Therapeutics reports Q1 2026 net loss of $31.0M; revenues $1.4M, cash $27.6M - TradingView
TradingKey - TradingKey
Sangamo Therapeutics : Zinc finger fusions and synthetic DNA donor engineering improve the performance of reprogrammed modular integrases at the TRAC locus - marketscreener.com
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call - The Manila Times
Sangamo Therapeutics (SGMO) Eps Diluted (TTM) - Zacks Investment Research
Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from S&P TMI Index - marketscreener.com
Sangamo Therapeutics, Inc.(OTCPK: SGMO) dropped from S&P Global BMI Index - marketscreener.com
SGMO Price Today: Sangamo Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
SGMO Stock Could Be Ready for a Major Rebound as Investor Interest Grows - vocal.media
SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Sangamo Therapeutics(SGMO) Stock Options Chain | Quotes & News - Moomoo
Free cash flow of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
CapEx per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Basic earnings per share (basic EPS) of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Gross margin % of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
0.73%
Capitalizzazione:
|
Volume (24 ore):